In latest House Select Committee on the CCP, outbound investment restrictions get favorable view.
CPA advocates for domestic manufacturing of essential generic drugs, personal protective equipment (PPE), and other critical health care products because it is vital for our country’s health security and national security.
COVID-19 showed that in a pandemic, the United States cannot depend on other countries for essential medicines and other medical supplies. Many countries banned exports of them to assure they had enough for their own people.
It is a national security imperative that our country is not dependent on unfriendly nations. At the height of the pandemic, the Chinese Communist Party threatened to withhold essential drugs from America. This threat reveals the inclination by some nations to use medicines as an economic and geopolitical weapon. We must have the capability to manufacture medicines and medical supplies necessary for the country’s public health and survival.
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.